Advanced Drug Modalities Fuel Cardiovascular Therapeutics Future Growth Potential
Globally, CVD is the leading cause of death, with resurgence in higher-income countries and higher prevalence in low- and middle-income countries. While there have been many advancements made to this indication using wearables and advanced diagnostics and devices, growth in therapeutics has been veiled. Traditional pharmacotherapy faces the drawback of being highly invasive and causing damage to the liver, kidneys, and other organs, as well as having other side effects. In addition, cardiac surgeries are complex procedures with the possibility of postoperative complications.
For several years, small-molecule therapies have dominated cardiovascular therapies. However, they may not have uniform effectiveness in all patients; hence, targeted therapeutics are required. There was a brief period when the number of drug approvals for CVDs was lower than for other indications and drugs being developed for similar mechanisms of action; nevertheless, the industry has grown with the development of new enabling technologies that can assist the development of targeted therapies, such as gene therapies, gene editing platforms, RNA therapies, and regenerative medicine. Targeted therapies can be explored for CVDs, as some diseases (hypertrophic cardiomyopathy [HCM], for example) are caused by the MYH6 gene mutation or an abnormal protein, such as the fibroblast activation protein (FAP), in cardiac fibrosis.
This study explores the pipeline of drugs in development and emphasizes how the oldest modality, small molecules, is still being actively pursued and adopted, even amidst the growing number of gene therapies, which are likely to become the standard of care in the next 10-15 years.
The study also discusses various technological advancements, novel innovations, and the investor ecosystem. It does not include details about drug devices, diagnostic techniques, and remote monitoring technologies.
Strategic Imperatives
Why Is It Increasingly Difficult to Grow?
The Strategic Imperative 8
The Impact of the Top 3 Strategic Imperatives on the Pipeline Assessment for Cardiovascular Diseases
Growth Opportunities Fuel the Growth Pipeline Engine
Research Methodology
Growth Opportunity Analysis
Scope of Analysis
Segmentation
Growth Generator
Growth Drivers
Growth Restraints
Burgeoning Need for Advanced Therapeutics for CVDs
CVDs: An Introduction
CVDs: Development of Therapeutic Drugs
CVDs: Risk Factors
CVDs: Trends in Drug Development
Cardiovascular Therapeutics: Current Unmet Needs
Need for Advanced (Precision) Therapies in Cardiology
Overview of the Cardiovascular Drug Pipeline
Small-molecule Therapeutics: A Snapshot
Small-molecule Therapeutics: Important Developments
Protein-based Therapeutics, Antibodies: A Snapshot
Antibodies: Important Developments
Protein-based Therapeutics, Peptide-based Therapies: Snapshot and Important Developments
Gene Therapies: A Snapshot
Gene Therapies: Important Developments
RNA Therapeutics: A Snapshot
RNA Therapeutics: Important Developments
Development of Cardiovascular Nucleic Acid Drugs
Regenerative Medicine in Cardiovascular Therapeutics
Regenerative Medicine for CVDs
Cardiovascular Drug Development Progress per Modality and Disease Condition
University Research in Cardiovascular Drug Development
Growth Opportunities for Advanced Therapies
Research Areas
Development of Cardiovascular Gene Therapies
Advances in In-vitro and In-vivo Models for CVD Modeling
Drug Discovery Platforms for CVDs
Enabling Technologies (AI/ML, Omics)
Using Omics to Accelerate Precision Medicine Development
Using AI in Cardiovascular Drug Discovery and Development
Large Pharmaceutical Companies’ Rising Strategic Moves
University Spin-offs Bring Innovative Therapies into the Limelight
Drug Development Partnerships Fuel the Process of Bringing Innovative Therapies to the Market
Large Pharmaceutical Companies are Actively Boosting Their Drug Pipelines Through Acquisitions
Growth of Funding Opportunities in the Development of Targeted Cardiovascular Therapies
Stakeholder Ecosystem: Key Takeaways
Growth Opportunity Universe
Growth Opportunity 1: Using New In-vitro Models to Quickly Translate Drugs from the Preclinical Stage to Clinical Trial Success
Growth Opportunity 2: Using AI/ML in Drug Discovery and Development
Growth Opportunity 3: Using Multi-omics to Achieve Precise CVD Treatments